NF-κB prevents β cell death and autoimmune diabetes in NOD mice
- Sunshin Kim*,
- Isabelle Millet†,
- Hun Sik Kim*,
- Ja Young Kim*,
- Myoung Sook Han*,
- Moon-Kyu Lee*,
- Kwang-Won Kim*,
- Robert S. Sherwin†,‡,
- Michael Karin§,‡, and
- Myung-Shik Lee*,‡
- *Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Kangnam-ku, Seoul 135-710, Korea;
- †Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, TMP532, P.O. Box 208020, New Haven, CT 06520-8020; and
- §Department of Pharmacology, School of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0723
-
Contributed by Michael Karin, December 6, 2006 (received for review November 1, 2006)
Abstract
Whereas NF-κB has potent antiapoptotic function in most cell types, it was reported that in pancreatic β cells it serves a proapoptotic function and may contribute to the pathogenesis of autoimmune type 1 diabetes. To investigate the role of β cell NF-κB in autoimmune diabetes, we produced transgenic mice expressing a nondegradable form of IκBα in pancreatic β cells (RIP-mIκBα mice). β cells of these mice were more susceptible to killing by TNF-α plus IFN-γ but more resistant to IL-1β plus IFN-γ than normal β cells. Similar results were obtained with β cells lacking IκB kinase β, a protein kinase required for NF-κB activation. Inhibition of β cell NF-κB accelerated the development of autoimmune diabetes in nonobese diabetic mice but had no effect on glucose tolerance or serum insulin in C57BL/6 mice, precluding a nonphysiological effect of transgene expression. Development of diabetes after transfer of diabetogenic CD4+ T cells was accelerated in RIP-mIκBα/nonobese diabetic mice and was abrogated by anti-TNF therapy. These results suggest that under conditions that resemble autoimmune type 1 diabetes, the dominant effect of NF-κB is prevention of TNF-induced apoptosis. This differs from the proapoptotic function of NF-κB in IL-1β-stimulated β cells.
Footnotes
- ‡To whom correspondence may be addressed. E-mail: robert.sherwin{at}yale.edu, karinoffice{at}ucsd.edu, or mslee{at}smc.samsung.co.kr
-
Author contributions: S.K., R.S.S., M.K., and M.-S.L. designed research; S.K., I.M., H.S.K., J.Y.K., M.S.H., and M.-S.L. performed research; I.M., M.-K.L., K.-W.K., R.S.S., M.K., and M.-S.L. contributed new reagents/analytic tools; S.K., H.S.K., M.-K.L., K.-W.K., R.S.S., M.K., and M.-S.L. analyzed data; and M.K. and M.-S.L. wrote the paper.
-
The authors declare no conflict of interest.
-
This article contains supporting information online at www.pnas.org/cgi/content/full/0610690104/DC1
- Abbreviations:
- iNOS,
- inducible NO synthase;
- NOD,
- nonobese diabetic;
- T1D,
- type 1 diabetes;
- T2D,
- type 2 diabetes.
- © 2007 by The National Academy of Sciences of the USA





